61130-13-0

Basic information

• Product Name: Phosphonium, [(4-iodophenyl)methyl]triphenyl-, bromide
• CAS NO: 61130-13-0
• Molecular Formula: C25H21IP.Br
• Molecular Weight: 559.224
• Mol File: 61130-13-0.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Phosphonium, [(4-iodophenyl)methyl]triphenyl-, bromide(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonium, [(4-iodophenyl)methyl]triphenyl-, bromide(61130-13-0)
• EPA Substance Registry System: Phosphonium, [(4-iodophenyl)methyl]triphenyl-, bromide(61130-13-0)

Safety Data

• Hazardous Substances Data: 61130-13-0(Hazardous Substances Data)

Upstream product

• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 603-35-0 triphenylphosphine 
• 624-31-7 4-tolyl iodide 

Downstream Products

• 57083-13-3 4-Iod-3',4'-dimethoxy-trans-stilben 
• 57083-03-1 (E)-1-(m-Methoxyphenyl)-2-(p-iodphenyl)-ethylen 
• 58358-53-5 (E)-1-(o-Methoxyphenyl)-2-(p-iodphenyl)-ethylen 
• 143662-59-3 3-(4'-Iodstyryl)-pyridin 
• 743436-35-3 1-(p-iodophenyl)-2-(2'-thienyl)ethene 
• 1426083-92-2 tert-butyl [5-(4-iodostyryl)-2,2-dimethyl-1,3-dioxan-5-yl]carbamate 
• 621-23-8 1,2,3-trimethoxybenzene 

Relevant articles and documents

Substituted dienes prepared from betulinic acid – Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters

A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.

PHENACENE COMPOUND, METHOD FOR PRODUCING PHENACENE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT

PROBLEM TO BE SOLVED: To provide a phenacene compound having a high fluorescence yield. SOLUTION: The present invention provides a phenacene compound represented by formula (1), where A is a group represented by formula (2); Z1 and Z2/sup

N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR IDENTIFICATION OF SERINE HYDROLASE TARGETS

Provided herein are N-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and composition